Cardiff Historical Financial Ratios
| CRDF Stock | USD 4.03 0.06 1.51% |
Cardiff Oncology is presently reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0074, PTB Ratio of 1.04 or Days Sales Outstanding of 167 will help investors to properly organize and evaluate Cardiff Oncology financial condition quickly.
Cardiff |
About Cardiff Financial Ratios Analysis
Cardiff OncologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cardiff Oncology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cardiff financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cardiff Oncology history.
Cardiff Oncology Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cardiff Oncology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cardiff Oncology sales, a figure that is much harder to manipulate than other Cardiff Oncology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Cardiff Oncology dividend as a percentage of Cardiff Oncology stock price. Cardiff Oncology dividend yield is a measure of Cardiff Oncology stock productivity, which can be interpreted as interest rate earned on an Cardiff Oncology investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Cardiff Oncology. There are two different methods for calculating Cardiff Oncology invested capital: operating approach and financing approach. Understanding Cardiff Oncology invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Most ratios from Cardiff Oncology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cardiff Oncology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.At this time, Cardiff Oncology's EV To Sales is most likely to increase significantly in the upcoming years. The Cardiff Oncology's current Days Of Inventory On Hand is estimated to increase to 0.000031, while PTB Ratio is projected to decrease to 1.04.
| 2022 | 2024 | 2025 (projected) | Dividend Yield | 0.006782 | 0.0078 | 0.00741 | Price To Sales Ratio | 158.13 | 121.95 | 201.15 |
Cardiff Oncology fundamentals Correlations
Click cells to compare fundamentals
Cardiff Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiff Oncology fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 1.0K | 653.4 | 158.13 | 135.5 | 121.95 | 201.15 | |
| Ptb Ratio | 2.93 | 1.67 | 0.57 | 0.95 | 1.09 | 1.04 | |
| Days Sales Outstanding | 319.59 | 543.94 | 729.05 | 215.41 | 193.87 | 166.52 | |
| Book Value Per Share | 6.14 | 3.6 | 2.44 | 1.56 | 1.4 | 1.33 | |
| Free Cash Flow Yield | (1.8) | (0.044) | (0.0991) | (0.57) | (0.48) | (0.55) | |
| Operating Cash Flow Per Share | (2.22) | (0.78) | (0.59) | (0.69) | (0.62) | (0.65) | |
| Stock Based Compensation To Revenue | 4.82 | 9.01 | 11.03 | 9.24 | 8.32 | 5.83 | |
| Pb Ratio | 2.93 | 1.67 | 0.57 | 0.95 | 1.09 | 1.04 | |
| Ev To Sales | 670.57 | 628.82 | 122.82 | 95.52 | 85.97 | 152.59 | |
| Free Cash Flow Per Share | (0.79) | (0.6) | (0.8) | (0.7) | (0.63) | (0.67) | |
| Roic | (0.15) | (0.2) | (0.35) | (0.63) | (0.73) | (0.69) | |
| Net Income Per Share | (0.92) | (0.71) | (0.86) | (0.93) | (0.83) | (0.88) | |
| Payables Turnover | 17.01 | 8.22 | 0.35 | 0.1 | 0.12 | 0.11 | |
| Sales General And Administrative To Revenue | 22.45 | 32.97 | 34.15 | 26.73 | 24.05 | 17.48 | |
| Research And Ddevelopement To Revenue | 30.7 | 48.4 | 70.23 | 67.33 | 60.6 | 63.63 | |
| Capex To Revenue | 0.58 | 0.57 | 2.31 | 1.19 | 1.07 | 1.02 | |
| Cash Per Share | 6.27 | 3.61 | 2.41 | 1.67 | 1.93 | 1.83 | |
| Pocfratio | (23.02) | (10.18) | (1.8) | (2.14) | (1.93) | (2.02) | |
| Payout Ratio | (1.5) | (1.26) | (8.65E-4) | (0.011) | (0.009934) | (0.0104) | |
| Capex To Operating Cash Flow | (0.013) | (0.008898) | (0.0264) | (0.0188) | (0.017) | (0.0178) | |
| Days Payables Outstanding | 21.46 | 44.38 | 1.1K | 3.6K | 4.1K | 2.4K | |
| Roe | (0.15) | (0.2) | (0.35) | (0.59) | (0.68) | (0.72) | |
| Ev To Operating Cash Flow | (15.04) | (9.8) | (1.4) | (1.51) | (1.36) | (1.43) | |
| Pe Ratio | (19.48) | (8.46) | (1.63) | (1.6) | (1.44) | (1.51) | |
| Return On Tangible Assets | (0.14) | (0.19) | (0.32) | (0.51) | (0.46) | (0.48) | |
| Ev To Free Cash Flow | (14.85) | (9.71) | (1.37) | (1.48) | (1.33) | (1.4) | |
| Net Debt To E B I T D A | 6.91 | 0.31 | 0.34 | 0.43 | 0.39 | 0.68 | |
| Current Ratio | 21.79 | 22.28 | 14.25 | 7.41 | 6.67 | 6.55 | |
| Tangible Book Value Per Share | 6.14 | 3.6 | 2.44 | 1.56 | 1.4 | 1.33 | |
| Receivables Turnover | 1.14 | 0.67 | 0.5 | 1.69 | 1.95 | 1.85 | |
| Graham Number | 11.3 | 7.59 | 6.87 | 5.71 | 6.56 | 6.24 | |
| Shareholders Equity Per Share | 6.14 | 3.6 | 2.44 | 1.56 | 1.4 | 1.33 |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth 0.17 | Return On Assets | Return On Equity |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.